Invesco Ltd. Fulcrum Therapeutics, Inc. Transaction History

Invesco Ltd.

$499 Billion
Q3 2024

A detailed history of Invesco Ltd. transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 30,662 shares of FULC stock, worth $91,679. This represents 0.0% of its overall portfolio holdings.

Number of Shares

30,662

Previous 31,043 1.23%

Holding current value

$91,679

Previous $192,000 43.23%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$3.18 - $9.74 $1,211 - $3,710	-381 Reduced 1.23%	30,662 $109,000
Q2 2024 Aug 13, 2024	SELL	$5.98 - $9.31 $2.78 Million - $4.34 Million	-465,636 Reduced 93.75%	31,043 $192,000
Q1 2024 May 14, 2024	BUY	$6.7 - $12.0 $137,169 - $245,676	20,473 Added 4.3%	496,679 $4.69 Million
Q4 2023 Feb 12, 2024	BUY	$3.18 - $6.86 $1.51 Million - $3.27 Million	476,206 New	476,206 $3.21 Million
Q1 2023 May 12, 2023	SELL	$2.83 - $13.99 $1,440 - $7,120	-509 Reduced 3.92%	12,469 $35,000
Q4 2022 Feb 13, 2023	BUY	$5.01 - $8.35 $8,702 - $14,503	1,737 Added 15.45%	12,978 $94,000
Q3 2022 Nov 14, 2022	BUY	$4.92 - $9.1 $693 - $1,283	141 Added 1.27%	11,241 $90,000
Q2 2022 Aug 15, 2022	SELL	$4.2 - $24.0 $891,912 - $5.1 Million	-212,360 Reduced 95.03%	11,100 $55,000
Q1 2022 May 16, 2022	BUY	$9.96 - $23.65 $1.16 Million - $2.74 Million	115,993 Added 107.93%	223,460 $5.28 Million
Q4 2021 Feb 14, 2022	SELL	$14.0 - $28.44 $6.84 Million - $13.9 Million	-488,590 Reduced 81.97%	107,467 $1.9 Million
Q3 2021 Nov 15, 2021	BUY	$7.28 - $30.97 $4.34 Million - $18.5 Million	596,057 New	596,057 $16.8 Million

Others Institutions Holding FULC

# of Institutions

150

Shares Held

52.2M

Call Options Held

6.91M

Put Options Held

1.9M

View Full List

About Fulcrum Therapeutics, Inc.

Ticker FULC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,038,900
Market Cap $156M
Description
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...

More about FULC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account